Table 1.
Patients' baseline characteristics (N=88)
| Characteristics | No. | Percentage |
|---|---|---|
| Age (years) | ||
| ≤60 | 28 | 31.8 |
| >60 | 60 | 68.2 |
| Gender | ||
| Male | 65 | 73.9 |
| Female | 23 | 26.1 |
| ECOG performance status | ||
| 0 | 37 | 42.0 |
| 1 | 51 | 58.0 |
| Child-Pugh classification | ||
| A | 83 | 94.3 |
| B | 5 | 5.7 |
| Postoperative recurrence | ||
| Yes | 18 | 20.5 |
| No | 70 | 79.5 |
| Previous treatment | ||
| Yes | 28 | 31.8 |
| No | 60 | 68.2 |
| Subsequent treatment | ||
| Yes | 29 | 33.0 |
| No | 59 | 67.0 |
| Combined treatment | ||
| Yes | 42 | 47.7 |
| No | 46 | 52.3 |
| TAI | ||
| Yes | 31 | 35.2 |
| No | 57 | 64.8 |
| Strengthen embolization | ||
| Yes | 19 | 21.6 |
| No | 69 | 78.4 |
| No. of tumor | ||
| Solitary | 26 | 29.5 |
| Multiple | 62 | 70.5 |
| Tumor location | ||
| Unilateral | 59 | 67.0 |
| Bilateral | 29 | 33.0 |
| Liver tumor burden | ||
| ≤25% | 41 | 46.6 |
| >25% ≤50% | 31 | 35.2 |
| >50% | 16 | 18.2 |
| Largest diameter (cm) | ||
| ≤5 | 32 | 36.4 |
| >5 | 56 | 63.6 |
| Cholangiectasis | ||
| Yes | 27 | 30.7 |
| No | 61 | 69.3 |
| Serum CA-125 (U/ml) | ||
| ≤35 | 57 | 64.8 |
| >35 | 31 | 35.2 |
| Serum CA-199 (U/ml) | ||
| ≤37 | 42 | 47.7 |
| >37 | 46 | 52.3 |
| Extrahepatic disease | ||
| Yes | 50 | 56.8 |
| No | 38 | 43.2 |
| Vascular invasion | ||
| Yes | 34 | 38.6 |
| No | 54 | 61.4 |
Data were presented as count and percentage.
ECOG, Eastern Cooperative Oncology Group; CA-125, carbohydrate antigen 125; CA-199, carbohydrate antigen 199; TAI, transcatheter arterial infusion.